<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224572</url>
  </required_header>
  <id_info>
    <org_study_id>201702008MIPB</org_study_id>
    <nct_id>NCT03224572</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin C on Quality of Life of Terminal Cancer Patients</brief_title>
  <official_title>The Effect of Vitamin C on Quality of Life of Terminal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determines whether high dose vitamin C is effective for quality of life in
      terminal cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator's project is a single medical center, randomized double- blinded trial. The
      target group is terminal cancer patients at Palliative care clinics. The experimental group
      will receive intravenous high-dose vitamin C 30 g in 500 ml normal saline in 1-hour infusion,
      once per week, and total 4-week treatment. The control group will receive 500 ml normal
      saline in 1-hour infusion, once per week, and total 4-week treatment. The primary outcome is
      the improvement of quality of life, measured by European Organization for Research and
      Treatment of cancer (EORTC). The secondary outcome is the survival analysis.The participants
      will be followed up weekly for 2 weeks, then bi-weekly for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment Randomized double-blinded controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The improvement of quality of life (QOL)</measure>
    <time_frame>6 months</time_frame>
    <description>QOL measured by European Organization for Research and Treatment of cancer Quality of Life Questionnaire (EORTC QLQ)-C30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival analysis</measure>
    <time_frame>6 months</time_frame>
    <description>death time of those who have completed the 4-week intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vitamin C Deficiency</condition>
  <arm_group>
    <arm_group_label>The study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study group will receive intravenous high-dose vitamin C 30 gm in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high-dose vitamin C 30gm</intervention_name>
    <description>High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.</description>
    <arm_group_label>The study group</arm_group_label>
    <other_name>ascorbic acid 30 gm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>500ml normal saline, once per week, and total 4-week treatment</description>
    <arm_group_label>The study group</arm_group_label>
    <arm_group_label>The control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Terminal colon cancer patients without pleural effusions, who will not receive any
        curative radiotherapy or chemotherapy.

        Exclusion Criteria:

          -  Renal metastasis or obstructive uropathy by radiology

          -  Nephrotic syndrome

          -  Creatinine over 1.5mg/dl

          -  Urolithasis

          -  Under other folk therapy or vitamin infusion therapy

          -  Those who can't exercise the right of consent

          -  Those who can't answer the questionaires

          -  Glucose-6-Phosphate Dehydrogenase Deficiency

          -  Severe lower leg edema or general edema
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chin-Ying Chen, MD, MHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chin-Ying Chen, MD, MHSc</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>66828</phone_ext>
    <email>crystalcychen@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chin-Ying Chen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin C</keyword>
  <keyword>quality of life</keyword>
  <keyword>terminal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid Deficiency</mesh_term>
    <mesh_term>Scurvy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

